Duraes AR, et al. - Researchers assessed the safety and efficacy of rivaroxaban 15 mg administered twice daily for a period of 90 days in 7 patients chosen between May 2017 and January 2018 who underwent isolated mitral valve replacement with a mechanic prosthesis and had unstable INR control at least 3 months following surgery. Observations during 3 months of follow-up did not include a single case of intracardiac thrombus, reversible ischemic neurological deficit, ischemic or hemorrhagic stroke, hospitalization or death. Two patients eliminated the presence of spontaneous echo contrast. Similar mean and peak pressure gradients, peak velocity, effective orifice area and PHT were found before and after the intervention. Overall, no thromboembolic or bleeding events were reported with this treatment regimen in this patient population.